Topics

Companies Related to "Artificial Neurons Chip Developed Treat Chronic Diseases" [Most Relevant Company Matches] RSS

06:20 EST 21st January 2020 | BioPortfolio

Here are the most relevant search results for "Artificial Neurons Chip Developed Treat Chronic Diseases" found in our extensive corporate database of over 50,000 company records.

Showing "Artificial Neurons Chip Developed Treat Chronic Diseases" Companies 1–25 of 5,900+

Relevant

Trophos SA

Trophos is a biopharmaceutical company committed to the discovery and development of novel therapeutic compounds to treat neurodegenerative diseases.Trophos has a fully integrated pre-clinical and clinical capability. Our discovery strategy is based on screening chemical collections of small molecules on models of sick neurons, using the class of neurons affected in each type of disease. Since com...


Pulmatrix, Inc.

Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM™), are a novel approach to prevent and treat acute exacerbations an...

Energex Systems, Inc.

Energex Systems, Inc. is dedicated to the development, manufacturing and marketing of patented therapeutic medical devices that use energy sources innovatively to treat chronic conditions and diseases. Founded in 1999, the company has developed two very unique, patented medical technologies, both having international appeal to patients and the medical community alike because of the conditions they...


Pulmatrix

Pulmatrix is discovering and developing a new class of therapies --inhaled cationic airway lining modulators (iCALM) –to prevent and treat respiratory infections and acute exacerbations of chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such ...

iPierian, Inc.

iPierian is a pioneering biopharmaceutical company focusing on harnessing the power of induced pluripotent stem cells (iPSCs) to discover novel therapies that are effective in addressing the vast unmet patient needs in neurodegenerative diseases. The company is focused on developing monoclonal antibodies against targets of the Tau protein and the Complemen...

WellDoc

WellDoc®, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, is focused on simplifying the way chronic diseases are managed through a collaborative, life-changing approach that breaks down the barriers of engagement and therapy adherence by providing patients and their heal...

Madaus AG

As an international phytopharmaceutical company, Madaus AG has developed and currently manufactures highly effective medicines of plant origin together with health-promoting products for "Natural Prevention". The objective of all products of Madaus is to treat the fundamental causes of disease, not merely the symptoms, and thereby to prevent diseases from occurring or at least from becoming chroni...

Maas Biolab LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA, developing Mitogard®, the only cyclosporine formula designed for CSF delivery, to treat amyotrophic lateral sclerosis. Maas Biolab holds FDA Orphan Drug Designation for cyclosporine to treat ALS and world patents for cyclosporine neuroprotection against chronic neurological disea...

Chromos

Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders. BUSINESS FOCUS Developing biological therapies for the treatment of multiple sclerosis (MS), thrombotic disorders and other inflammatory diseases . PROPRIETARY PRODUCTS Two humanized monoclonal antibodies with novel mechanisms of action. CHR-1103 is being developed i...

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by...

Hesperos, Inc.

Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a...

Neuronascent, Inc

Neuronascent began operations in a fully functional cell culture facility in Maryland. Neuronascent is in the process of developing small-molecule therapeutics for Alzheimer’s disease and depression as the main indications for its “neurogenesis” program. An orally-active, neurogenic agent could promote the formation of new neurons in key areas of the brain, replace damaged neurons, and reduc...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and gr...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate ...

TNI BioTech, Inc.

TNI BioTech, Inc. is a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, ch...

Colby Pharmaceutical Company

Colby is a privately held company based in Madison, WI and San Jose, CA. Colby is developing new oral small molecule signal transduction modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain, infectious diseases, and neurodegenerative diseases. Colby’s lead small molecule candidates have unique mechanisms of ac...

Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases includi...

BrainCells Inc.

BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its proprietary human neural stem cell platform technology to identify novel pathways for new therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which stem cells in the adult human brain produce new brain tissue, including ne...

Novocell, Inc

Novocell’s goal is to develop a renewable source of specialized cells that can be used to treat chronic cellular diseases. To achieve this goal, Novocell is uniquely positioned to exploit human stem cell engineered product opportunities using its proprietary cell encapsulation technology. Combined with Novocell's expertise in cell transplantation, these technologies will allow large numbers of p...

Silicon Biosystems

Silicon Biosystems, S.p.A. is based in Bologna, Italy and has developed a set of proprietary solutions called lab-on-a-chip technologies, targeted at miniaturized cell-biology testing. Silicon Biosystems is one of the most innovative start-ups in the field of "lab-on-a-chip," based on active substrates, as testified by a number of awards and recognitions. ...

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.Product Candidate PortfolioThe Company’s broad drug developm...

Novalung, Inc.

Novalung's mission is to create new solutions for the treatment of lung failure with innovative artificial lungs that "breathe" outside the patient's body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to rather experience their treatment while being awake, mobile and breathing easily. Founded in 2003, the ...

Q Chip Ltd

Q Chip was formed in 2003 to exploit breakthrough microparticle and microfluidic technologies developed at Cardiff University. The company has rapidly established itself as one of the leading developers of delivery systems for the new advanced therapeutics of the post-Genomics age. These systems revolve around proprietary PolyQules, combining drug with polymer to form solid microparticles which ca...

Graybug Vision, Inc.

Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to ...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...


More From BioPortfolio on "Artificial Neurons Chip Developed Treat Chronic Diseases"

Quick Search

Corporate Database Quicklinks